Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CCR6 | P51684 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1069872 | 0.85 | GPR3 (0.37) | ALDH1A1LMNAALOX15PKMMAPT | |
| SCHEMBL1064079 | 0.82 | GPR3 (0.34) | DRD1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL1068484 | 0.78 | — | — | |
| SCHEMBL1067893 | 0.78 | — | — | |
| SCHEMBL359672 | 0.78 | — | — | |
| SCHEMBL900706 | 0.77 | DRD1 (0.38) | DRD1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL900115 | 0.76 | DRD1 (0.37) | DRD1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL1067320 | 0.76 | DRD1 (0.37) | DRD1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL4918787 | 0.75 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL1067709 | 0.75 | MEN1 (0.31) | MEN1KMT2ALMNAHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6436961-B1 | SUBSTANCE P RECEPTOR ANTAGONIST; 2-PHENYL-3-BENZYLAMINOPIPERIDINES | PFIZER INC | 2002-08-20 | — | — | US | claimed |
| EP-3303337-B1 | FUSED TRICYCLIC IMIDAZO PYRAZINES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-05-27 | — | — | EP | disclosed |
| US-10472362-B2 | Fused tricyclic imidazo pyrazines as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2019-11-12 | — | — | US | disclosed |
| EP-3080114-B1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-10-02 | — | — | EP | disclosed |
| EP-3080113-B1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-09-18 | — | — | EP | disclosed |
| EP-3080121-B1 | FUSED TRICYCLIC BENZIMIDAZOLES DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-09-04 | — | — | EP | disclosed |
| US-20180298006-A1 | Fused Tricyclic Imidazo Pyrazines as Modulators of TNF Activity | UCB S.A. (BE) | 2018-10-18 | — | — | US | disclosed |
| US-10087179-B2 | Fused tricyclic imidazole derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-10-02 | — | — | US | disclosed |
| EP-3303337-A1 | FUSED TRICYCLIC IMIDAZO PYRAZINES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2018-04-11 | — | — | EP | disclosed |
| US-9932343-B2 | Fused tricyclic benzimidazoles derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-04-03 | — | — | US | disclosed |
| WO-2010149758-A1 | ANTIFUNGAL 1, 2, 4-TRIAZOLYL DERIVATIVES | BASF SE (DE) | 2010-12-29 | — | — | WO | disclosed |
| US-20100317515-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | BASF SE (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100311581-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | BASF SE (DE) | 2010-12-09 | — | — | US | disclosed |
| US-20100273651-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | BASF SE (DE) | 2010-10-28 | — | — | US | disclosed |
| EP-2235005-A2 | AZOLYLMETHYLOXIRANES, USE THEREOF AND AGENTS CONTAINING THE SAME | BASF SE (DE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009077500-A2 | AZOLYLMETHYLOXIRANES, USE THEREOF AND AGENTS CONTAINING THE SAME | BASF SE (DE) | 2009-06-25 | — | — | WO | disclosed |
| US-20080132538-A1 | Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | PFIZER INC | 2008-06-05 | — | — | US | disclosed |
| US-20050256162-A1 | Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
| US-6436961-B1 | SUBSTANCE P RECEPTOR ANTAGONIST; 2-PHENYL-3-BENZYLAMINOPIPERIDINES | PFIZER INC | 2002-08-20 | — | — | US | disclosed |
| EP-1172106-A2 | Use of fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles as substance P receptor antagonists | Pfizer Products Inc. (US) | 2002-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180298006-A1 | Fused Tricyclic Imidazo Pyrazines as Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | DRD1 3266/4885ALDH1A1 1598/4885MEN1 4123/4885 |
| US-20080132538-A1 | Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | NMUR2, NMUR1, NMBR | DRD1 1169/4885ALDH1A1 1666/4885MEN1 1738/4885 |
| US-20100317515-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | XDH, NOX5, TET1 | DRD1 1560/4885ALDH1A1 20/4885MEN1 1724/4885 |
| US-10087179-B2 | Fused tricyclic imidazole derivatives as modulators of TNF activity | TNF, TNFRSF1A, NFKBIA | DRD1 1667/4885ALDH1A1 1999/4885MEN1 3535/4885 |
| US-20050256162-A1 | Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | FPR3, CX3CR1, FPR1 | DRD1 628/4885ALDH1A1 1640/4885MEN1 2509/4885 |
| US-10472362-B2 | Fused tricyclic imidazo pyrazines as modulators of TNF activity | TNF, TNFRSF1A, TNFRSF9 | DRD1 3161/4885ALDH1A1 1283/4885MEN1 4096/4885 |
| US-20100273651-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | XDH, SQOR, NOX5 | DRD1 1470/4885ALDH1A1 14/4885MEN1 1585/4885 |
| US-20100311581-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | XDH, DAO, DHODH | DRD1 739/4885ALDH1A1 25/4885MEN1 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.